菠萝蛋白酶酶性清创与烧伤感染菌血症发生:一项回顾性队列研究
该单中心回顾性队列研究纳入2017年1月至2021年12月在苏黎世大学医院烧伤中心住院的269例重症成年烧伤患者,评估局部菠萝蛋白酶清创与菌血症发生的关联。完全校正竞争风险回归模型显示菠萝蛋白酶治疗与菌血症无关联(SHR 0.79,95%CI 0.42-1.48,p=0.47),ICU总体死亡率亦无显著差异(HR 0.55,95%CI 0.26-1.20,p=0.14)。
要点
- 269例重症成年烧伤患者中83例(31%)接受菠萝蛋白酶治疗,其中22例(27%)发生菌血症。
- 完全校正竞争风险模型未发现菠萝蛋白酶治疗与菌血症的关联(SHR 0.79,95%CI 0.42-1.48,p=0.47)。
- 菠萝蛋白酶治疗组与非治疗组ICU死亡率无显著差异(HR 0.55,95%CI 0.26-1.20,p=0.14)。
核心结论
- 本研究未证实重症烧伤患者局部使用菠萝蛋白酶与菌血症之间存在关联。
- 该发现可为循证实践提供信息,回应关于菠萝蛋白酶使用潜在风险的担忧,有助于制定更有效、更安全的烧伤创面管理策略。
研究设计与样本
- 单中心回顾性队列研究,纳入2017年1月至2021年12月在苏黎世大学医院烧伤中心住院的重症成年烧伤患者。
- 数据来自两个院内电子病历数据库,共纳入269例患者。
- 主要结局采用竞争风险回归模型分析局部菠萝蛋白酶治疗与菌血症发生的关联,并考虑死亡作为竞争风险。
- 次要结局采用Cox比例风险模型分析菠萝蛋白酶治疗与ICU总体死亡率的关系。
主要发现
- 269例患者中位年龄50岁,中位烧伤总面积19%。
- 61例(23%)患者在中位6天后首次发生菌血症。
- 83例(31%)患者接受菠萝蛋白酶治疗,其中22例(27%)发生菌血症。
- 完全校正竞争风险回归模型未发现菠萝蛋白酶治疗与菌血症的关联(SHR 0.79,95%CI 0.42-1.48,p=0.47)。
- 住院期间40例(15%)患者死亡,菠萝蛋白酶治疗组与非治疗组死亡率无显著差异(HR 0.55,95%CI 0.26-1.20,p=0.14)。
临床怎么用
- 原文结论指出本研究未证实局部菠萝蛋白酶与重症烧伤患者菌血症的关联,该发现可为循证实践提供信息。
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Debridement is crucial for effective wound management in patients with severe burn injuries, and bromelain, a proteolytic enzyme from pineapple stems, has emerged as a promising alternative for surgery. However, potential links of bromelain use to fever and sepsis have raised some concerns. Given the uncertainty as to whether this was caused by infection or other inflammatory sources, we aimed to investigate if the use of topical bromelain was associated with bacteremia. METHODS: This single-centre retrospective cohort study included critically ill adult patients with severe burn injuries hospitalised at the Burn Center of the University Hospital Zurich between January 2017 and December 2021. Data were collected from two in-hospital electronic medical records databases. Our primary outcome, the association between topical bromelain treatment and the development of bacteremia, was investigated using a competing risk regression model, taking into account the competing risk of death. As a secondary outcome, the relationship between bromelain treatment and overall ICU mortality was examined using a Cox proportional hazards model. RESULTS: The study included 269 patients with a median age of 50 years and median burnt total body surface area of 19%. A first bacteremia occurred in 61 patients (23%) after a median time of 6 days. Bromelain treatment was given to 83 (31%) of patients, with 22 (27%) of these developing bacteremia. In the fully adjusted competing risk regression model, no evidence for an association between bromelain treatment and bacteremia was found (SHR 0.79, 95%CI 0.42-1.48, p = 0.47). During hospital stay, 40 (15%) of patients died. There was no significant difference in mortality between patients treated with bromelain and those who were not (HR 0.55, 95%CI 0.26-1.20, p = 0.14). Among the five multidrug-resistant (MDR) pathogens identified, three were found in patients with bromelain treatment. CONCLUSION: Our study did not confirm an association between topical bromelain and bacteremia in patients with severe burn injuries. This finding can inform evidence-based practices by addressing concerns about potential risks of bromelain use, contributing to the development of more effective and safe burn wound management strategies.
引用
- Deplazes BC, Hofmaenner DA, Scheier TC, et al. Enzymatic debridement with bromelain and development of bacteremia in burn injuries: A retrospective cohort study. Burns. 2023. PMID: 38182450. doi:10.1016/j.burns.2023.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。